Cargando…
JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia
BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablish...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591900/ https://www.ncbi.nlm.nih.gov/pubmed/31234947 http://dx.doi.org/10.1186/s13287-019-1302-1 |
_version_ | 1783429801813475328 |
---|---|
author | Wei, Yimeng Hou, Huixing Zhang, Leisheng Zhao, Nianhuan Li, Chengwen Huo, Jiali Liu, Ying Zhang, Wenxia Li, Zongjin Liu, Dengke Han, Zhibo Zhang, Lei Song, Baoquan Chi, Ying Han, Zhongchao |
author_facet | Wei, Yimeng Hou, Huixing Zhang, Leisheng Zhao, Nianhuan Li, Chengwen Huo, Jiali Liu, Ying Zhang, Wenxia Li, Zongjin Liu, Dengke Han, Zhibo Zhang, Lei Song, Baoquan Chi, Ying Han, Zhongchao |
author_sort | Wei, Yimeng |
collection | PubMed |
description | BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablished, which also hinder the development and mechanism study of mesengenesis. METHODS: In this study, we aimed to establish a strategy for programming hESC differentiation into MSCs by practicing small-scale chemical compound screening. Then, we used flow cytometry, multi-lineage differentiation, and karyotype analyses to investigate the biological phenotypes of the derived hESC-MSCs. Also, to explore whether the derived cells had hematopoietic-supporting ability in vitro, we carried out the cobblestone formation and megakaryocytic differentiation experiments. To further evaluate the function of hESC-MSCs in vivo, we transplanted the cells into a mouse model with hind limb ischemia. RESULTS: By simultaneous treatments with a JAK/STAT antagonist and a DNA methylation inhibitor, the efficiency of generating hESCs into CD73(+) hESC-MPCs could reach 60% within 7 days. The derived cells further matured into hESC-MSCs, with comparable characteristics to those of adult MSCs in terms of surface markers, normal karyotype, and the potential for adipogenic, osteogenic, and chondrogenic differentiation. Functionally, hESC-MSCs had hematopoietic-supporting effects in vitro and could notably relieve symptoms of hind limb ischemia. CONCLUSIONS: In the study, we established a high-efficient procedure for large-scale generation of MSCs from hESCs, which would be of great help for genesis and mechanism studies of MSCs. Meanwhile, the derived cells provide an alternative for translational clinical research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-019-1302-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6591900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65919002019-07-08 JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia Wei, Yimeng Hou, Huixing Zhang, Leisheng Zhao, Nianhuan Li, Chengwen Huo, Jiali Liu, Ying Zhang, Wenxia Li, Zongjin Liu, Dengke Han, Zhibo Zhang, Lei Song, Baoquan Chi, Ying Han, Zhongchao Stem Cell Res Ther Research BACKGROUND: Mesenchymal stem/stromal cells (MSCs) derived from human embryonic stem cells (hESCs) are attractive for their hematopoietic-supporting or potential therapeutic effects. However, procedures for high-effective and scalable generation of MSCs from hESCs within 2 weeks are still unestablished, which also hinder the development and mechanism study of mesengenesis. METHODS: In this study, we aimed to establish a strategy for programming hESC differentiation into MSCs by practicing small-scale chemical compound screening. Then, we used flow cytometry, multi-lineage differentiation, and karyotype analyses to investigate the biological phenotypes of the derived hESC-MSCs. Also, to explore whether the derived cells had hematopoietic-supporting ability in vitro, we carried out the cobblestone formation and megakaryocytic differentiation experiments. To further evaluate the function of hESC-MSCs in vivo, we transplanted the cells into a mouse model with hind limb ischemia. RESULTS: By simultaneous treatments with a JAK/STAT antagonist and a DNA methylation inhibitor, the efficiency of generating hESCs into CD73(+) hESC-MPCs could reach 60% within 7 days. The derived cells further matured into hESC-MSCs, with comparable characteristics to those of adult MSCs in terms of surface markers, normal karyotype, and the potential for adipogenic, osteogenic, and chondrogenic differentiation. Functionally, hESC-MSCs had hematopoietic-supporting effects in vitro and could notably relieve symptoms of hind limb ischemia. CONCLUSIONS: In the study, we established a high-efficient procedure for large-scale generation of MSCs from hESCs, which would be of great help for genesis and mechanism studies of MSCs. Meanwhile, the derived cells provide an alternative for translational clinical research. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-019-1302-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-24 /pmc/articles/PMC6591900/ /pubmed/31234947 http://dx.doi.org/10.1186/s13287-019-1302-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wei, Yimeng Hou, Huixing Zhang, Leisheng Zhao, Nianhuan Li, Chengwen Huo, Jiali Liu, Ying Zhang, Wenxia Li, Zongjin Liu, Dengke Han, Zhibo Zhang, Lei Song, Baoquan Chi, Ying Han, Zhongchao JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title | JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title_full | JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title_fullStr | JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title_full_unstemmed | JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title_short | JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia |
title_sort | jnki- and dac-programmed mesenchymal stem/stromal cells from hescs facilitate hematopoiesis and alleviate hind limb ischemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591900/ https://www.ncbi.nlm.nih.gov/pubmed/31234947 http://dx.doi.org/10.1186/s13287-019-1302-1 |
work_keys_str_mv | AT weiyimeng jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT houhuixing jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT zhangleisheng jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT zhaonianhuan jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT lichengwen jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT huojiali jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT liuying jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT zhangwenxia jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT lizongjin jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT liudengke jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT hanzhibo jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT zhanglei jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT songbaoquan jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT chiying jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia AT hanzhongchao jnkianddacprogrammedmesenchymalstemstromalcellsfromhescsfacilitatehematopoiesisandalleviatehindlimbischemia |